Samrotamab
Based on 1 Customer Validation
Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric monoclonal antibody targeting LRRC15, with a Kd of 5.42 nM for human LRRC15. Samrotamab can be used to synthesize antibody-drug conjugates (ADC). Samrotamab disrupts the LRRC15-SCG5 signaling module, binds to a membrane-proximal conformational epitope within the C-terminal leucine-rich repeat region of LRRC15, and binds to the lateral edge of the LRR solenoid while leaving the canonical concave β-sheet surface fully exposed. Samrotamab reduces the viability of bladder cancer cells, inhibits clonogenic growth, impairs cell migration, and compromises cell invasion. Samrotamab induces compensatory upregulation of LRRC15 transcripts while suppressing the expression of SCG5 mRNA. Samrotamab is applicable to research related to urothelial carcinoma, sarcoma, osteosarcoma, and undifferentiated pleomorphic sarcoma.
For research use only. We do not sell to patients.
- Purity: 96.00%
- CAS No.: 2052591-32-7
- Molecular Weight:145.92 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
|
LRRC15 5.42 nM (Kd) |
Samrotamab (PR-1498487) (20 µg/mL; 24 h) reduces viability, clonogenic growth, migration, and invasion of human T24 muscle-invasive bladder carcinoma cells, while altering transcript levels of LRRC15 and SCG5[1].
Samrotamab (8.7-250 nM; 120 s contact time, 600 s dissociation time) binds purified human LRRC15 ectodomain with high affinity (KD = 5.42 nM) and specificity[2].
Samrotamab (25 µM; 0, 6, 60, 600, 6000 sec labeling time, overnight incubation at 4 °C) recognizes a conformational epitope formed by clustered leucine-rich repeat elements within the C-terminal region (residues 361-369, 383-393, 402-417) of purified human LRRC15 ectodomain[2].
Samrotamab (0.98-31.25 nM; 120 s contact time, 600 s dissociation time) binding to purified human LRRC15 ectodomain requires the C-terminal region encompassing residues 360-402; deletion of residues distal to 426 does not impact binding[2].
Samrotamab (0.13 mg/mL) Fab binds the lateral edge of the C-terminal leucine-rich repeat region of purified human LRRC15 ectodomain at 2.63 Å resolution, leaving the canonical concave β-sheet surface exposed[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human T24 muscle-invasive bladder carcinoma cells
-
Concentration:20 µg/mL
-
Incubation Time:24 h
-
Result:Targeting LRRC15 effectively inhibited the survival and proliferation of bladder cancer cells.
-
Cell Line:Human T24 muscle-invasive bladder carcinoma cells
-
Concentration:20 µg/mL
-
Incubation Time:24 h
-
Result:Induced compensatory upregulation of LRRC15 transcripts and significantly downregulated SCG5 mRNA expression.
-
Cell Line:Human T24 muscle-invasive bladder carcinoma cells
-
Concentration:20 µg/mL
-
Incubation Time:24 h
-
Result:Significantly reduced the migratory capacity of cells.
-
Cell Line:Human T24 muscle-invasive bladder carcinoma cells
-
Concentration:20 µg/mL
-
Incubation Time:24 h
-
Result:Significantly attenuated the invasive ability of the cells.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded Samrotamab on AHC2 biosensor, can bind LRRC15 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78172) with an affinity constant of 5.759E-10 M as determined in BLI assay.
Chemical Information
-
CAS No. 2052591-32-7
-
Appearance Liquid
-
Molecular Weight 145.92 kDa
-
Color Colorless to light yellow
-
SMILES
[Samrotamab]
-
Synonyms
PR-1498487
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Dong SW, et al. The role of LRRC15-SCG5 in ECM protein binding as a prognostic signature for urothelial carcinoma. American journal of cancer research. 2025;15(5):2301-2318. [Content Brief]
[3]. Demetri GD, et al. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Jul 01;27(13):3556-3566. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)